Identification of a novel therapeutic target in driver-negative nonsmall cell lung cancer

Molecular targeted therapy against driver gene aberrations has a significantly high positive response rate compared with traditional cytotoxic chemotherapies, and has thus dramatically changed the treatment strategies for malignant tumors, including non-small cell lung cancer (NSCLC) (1). Lung adenocarcinoma (LADC) can be treated with targeted therapy against driver gene aberrations using tyrosine kinase inhibitors (TKIs).